Physician profile
Jerad Hyde
NPI 1538744453
$4,522.00
in general payments reported to CMS, 2019-2025
42 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $423 · 2023: $1,065 · 2024: $1,111 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,424 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.41 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,017.18 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Corcept Therapeutics | $390.36 | 2024-2025 | Korlym |
| Abbvie INC. | $258.35 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.50 | 2023-2025 | |
| Astellas Pharma US INC | $217.22 | 2021-2025 | Veozah |
| Axsome Therapeutics, INC. | $207.78 | 2022-2025 | Auvelity |
| Amgen INC. | $179.89 | 2023-2025 | Otezla, Repatha, Repatha |
| Antares Pharma, INC. | $177.14 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $174.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.47 | 2022-2024 | Jardiance |
| Pfizer INC. | $116.79 | 2023-2025 | |
| Shield Therapeutics INC | $116.53 | 2023-2025 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $116.11 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.03 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $86.71 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerad Hyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.